연구동향 분석

알츠하이머병의 새로운 생물학적 정의: 2018 National Institute on Aging-Alzheimer’s Association Research Framework 소개

장재원 김상윤 2019년

논문상세정보
인용/피인용
' 알츠하이머병의 새로운 생물학적 정의: 2018 National Institute on Aging-Alzheimer’s Association Research Framework 소개' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Biomarkers
  • alzheimer disease
  • research
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
453 0

0.0%

' 알츠하이머병의 새로운 생물학적 정의: 2018 National Institute on Aging-Alzheimer’s Association Research Framework 소개' 의 참고문헌

  • Validating novel tau positron emission tomography tracer [F-18]-AV-1451(T807)on postmortem brain tissue
    Marquié M [2015]
  • Toward defining the preclinical stages of Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
    Sperling RA [2011]
  • The significance of medial temporal lobe atrophy : a postmortem MRI study in the very old
    Barkhof F [2007]
  • The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging
    Gordon BA [2016]
  • The diagnosis of mild cognitive impairment due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
    Albert MS [2011]
  • The diagnosis of dementia due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
    McKhann GM [2011]
  • Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly
    Chhatwal JP [2016]
  • Tau imaging : early progress and future directions
  • Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
    Brier MR [2016]
  • Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis
    Knopman DS [2013]
  • Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease : a voxelwise PiB-PET longitudinal study
    Villain N [2012]
  • Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
    Visser PJ [2009]
  • Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles
  • Pathological correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies
    Marquié M [2017]
  • Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics : a retrospective study
    Murray ME [2011]
  • National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease : a practical approach
    Montine TJ [2012]
  • National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease
    Hyman BT [2012]
  • NIA-AA Research Framework : toward a biological definition of Alzheimer’s disease
    Jack CR [2018]
  • Mild to moderate Alzheimer dementia with insufficient neuropathological changes
  • Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
    Jack CR [2011]
  • Injury markers predict time to dementia in subjects with MCI and amyloid pathology
  • In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease
  • Impact of the biological definition of Alzheimer’s disease using amyloid, tau and neurodegeneration(ATN) : what about the role of vascular changes, inflammation, Lewy body pathology
    Gauthier S [2018]
  • High performance plasma amyloid-β biomarkers for Alzheimer’s disease
    Nakamura A [2018]
  • Flortaucipir tau PET imaging in semantic variant primary progressive aphasia
    Makaretz SJ [2018]
  • Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease : results from the swedish mortality registry
  • Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer’s disease
    Besson FL [2015]
  • Clinical and biomarker changes in dominantly inherited Alzheimer’s disease
    Bateman RJ [2012]
  • Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
    Blennow K [2010]
  • CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease
    Buerger K [2006]
  • Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s disease
    Chételat G [2016]
  • Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred : a cross-sectional study
    Fleisher AS [2015]
  • Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample
    La Joie R [2018]
  • Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
    Mattsson N [2017]
  • An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease
    Jack CR Jr [2012]
  • Amyloid-β imaging with pittsburgh compound B and florbetapir : comparing radiotracers and quantification methods
    Landau SM [2013]
  • Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease : a prospective cohort study
  • Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
    Ovod V [2017]
  • Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later
    Roe CM [2013]
  • Advancing research diagnostic criteria for Alzheimer’s disease : the IWG-2 criteria
    Dubois B [2014]
  • A/T/N : an unbiased descriptive classification scheme for Alzheimer disease biomarkers
    Jack CR Jr [2016]